EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes—Reply

Gregory P Forlenza, Marcus S Schamberger, Bruce A Buckingham

JAMA · 2023

DOI: 10.1001/jama.2023.9113 ↗

Kurz gefasst

Leserbrief in der Zeitschrift JAMA, 2023. Verfasst von Gregory P Forlenza und 2 weiteren Autor:innen. Beteiligte Einrichtung: Barbara Davis Center, University of Colorado Anschutz Medical Campus, Aurora. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin-Secreting Cells, Verapamil, Calcium Channel Blockers. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Insulin-Secreting CellsVerapamilCalcium Channel BlockersChildHumans

Substanzen

VerapamilCalcium Channel Blockers

Autor:innen und Institutionen

  • Barbara Davis Center, University of Colorado Anschutz Medical Campus, Aurora.
  • Division of Pediatric Cardiology, Indiana University School of Medicine, Indianapolis.
  • Division of Pediatric Endocrinology, Stanford University, Palo Alto, California.

Zitieren

APA

Forlenza, G. P., Schamberger, M. S., & Buckingham, B. A. (2023). Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes—Reply. JAMA. https://doi.org/10.1001/jama.2023.9113

Vancouver

Forlenza GP, Schamberger MS, Buckingham BA. Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes—Reply. JAMA. 2023. doi:10.1001/jama.2023.9113

BibTeX
@article{Forlenza2023,
  author = {Forlenza, Gregory P and Schamberger, Marcus S and Buckingham, Bruce A},
  title = {Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes—Reply},
  journal = {JAMA},
  year = {2023},
  doi = {10.1001/jama.2023.9113}
}
Kostenlos starten →